ELIZABETH BRUSHABER: Open Payments
NPI 1477144939 · BILOXI, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,374 in 76 payments from 18 companies in 2025. Trend: 2023 $1,409 · 2024 $1,223 · 2025 $1,374
Food & beverage: $1,374
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 7 | $172 |
| Novo Nordisk Inc | 11 | $155 |
| Novartis Pharmaceuticals Corporation | 7 | $152 |
| Amgen Inc. | 9 | $137 |
| AstraZeneca Pharmaceuticals LP | 7 | $111 |
| Sumitomo Pharma America, Inc. | 5 | $96 |
| GlaxoSmithKline, LLC. | 5 | $91 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $79 |
| Astellas Pharma US Inc | 4 | $69 |
| Lilly USA, LLC | 4 | $66 |
Products named: REXULTI, LEQVIO, GEMTESA, OTEZLA, Ozempic, JARDIANCE, Veozah, MOUNJARO.
Industry payments across MS — which companies pay providers there.
